Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study

Basit Öğe Kaydı
dc.contributor.authorArtac, Mehmet
dc.contributor.authorTurha, Nazim Serdar
dc.contributor.authorKocer, Murat
dc.contributor.authorKarabulut, Bulent
dc.contributor.authorBozcuk, Hakan
dc.contributor.authorYalcin, Suayip
dc.contributor.authorKaraagac, Mustafa
dc.date.accessioned2024-02-23T14:26:57Z
dc.date.available2024-02-23T14:26:57Z
dc.date.issued2014
dc.departmentNEÜen_US
dc.description.abstractBackground. A high-risk group of patients with stage II colon cancer has been identified by the results of studies in Western populations. The aim of this study was to investigate the prognostic factors of adjuvant chemotherapy in Turkish patients with stage II colon cancer. Methods. A total of 554 stage II colon cancer patients were retrospectively enrolled in the study. Three hundred fifty-three patients had received adjuvant chemotherapy (5-FU-LV, FOLFOX or FLOX) and 201 had received no adjuvant chemotherapy. T4 tumor stage, lymphovascular invasion, perineural invasion, bowel obstruction and/or perforation, <12 harvested lymph nodes, and poor differentiation were defined as high-risk factors. Results. The median age of the patients was 62 years (range 26-88). The median disease-free survival (DFS) was 58.1 months (95% CI, 47.6 months to 68.5 months) in the non-treatment group and has not been reached in the treatment group (P <0.01). In univariate analysis, patient age >60 years and T4 tumor stage were statistically significant factors that affected DFS as poor prognostic factors. Adjuvant chemotherapy reduced the risk of recurrence with statistical significance (P <0.01). In multivariate analysis, patient age >60 years and T4 tumor stage were independent risk factors affecting DFS. In addition, adjuvant chemotherapy was an independent favorable prognostic factor for DFS (P <0.01). Conclusions. Clinical and pathological risk factors in patients with stage II colon cancer may be different in the Turkish population compared to other populations. Further prospective studies in colon cancer are needed to understand the differences in biology and risk factors between races.en_US
dc.identifier.doi10.1177/030089161410000205
dc.identifier.endpage148en_US
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue2en_US
dc.identifier.pmid24852857en_US
dc.identifier.scopus2-s2.0-84901387956en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage143en_US
dc.identifier.urihttps://doi.org/10.1177/030089161410000205
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14386
dc.identifier.volume100en_US
dc.identifier.wosWOS:000348335000005en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofTumori Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColon Canceren_US
dc.subjectAdjuvant Therapyen_US
dc.subjectPrognostic Factorsen_US
dc.titleDo high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu